Study guide

16.2 Sponsor, Investigator and Service-Provider Roles

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

16.2 Sponsor, Investigator and Service-Provider Roles

Key Takeaways Explain This Topic AI

Sponsors retain oversight of sponsor activities transferred to providers.

Investigators retain oversight of delegated site activities.

Provider interfaces need clear ownership, access, reporting and retention arrangements.

Last updated: October 2026

Sponsor, Investigator and Service-Provider Roles

A trial can involve a sponsor, CRO, investigator/institution, laboratories, imaging vendors, data managers, medical monitors and independent committees. E6(R3) expects responsibilities to be clear and documented. A task sent to another organisation does not disappear from oversight, and a service contract does not automatically give every employee authority to make clinical or regulatory decisions.

The sponsor initiates and manages the trial and maintains oversight of sponsor activities transferred to service providers. The investigator is responsible for site conduct and oversight of delegated site activities. A CRO can perform specified sponsor tasks, including monitoring, under the documented arrangement. The CRA works within that allocation; being the sponsor's representative is not authority to rewrite site source data or prescribe participant care.

Distinguish performance from accountability

A qualified coordinator may enter data, arrange visits and facilitate reporting. A pharmacist may manage product activities where permitted. A laboratory produces analytical results under its assigned role. Their work still needs suitable investigator or sponsor oversight according to whose responsibility is involved. Oversight should be proportionate to risk and supported by information, review and escalation.

For example, a sponsor outsources central laboratory testing. It should have an appropriate arrangement for the service, data transfer, quality issues and access to records. The investigator still needs timely relevant results for participant care and eligibility. If a critical result reaches a vendor dashboard but not the treating site, saying the laboratory contract was signed does not solve the safety failure.

Clinical and operational roles

Role Usual contribution Important boundary

Investigator/qualified site clinician Participant medical decisions and site oversight Delegation does not remove oversight

CRA/monitor Verify processes and data, communicate findings and follow-up Do not impersonate site staff or make independent treatment decisions

Sponsor medical monitor Medical/scientific safety support and sponsor review Does not replace the treating investigator's care responsibility

Data management Collection systems, queries, reconciliation and dataset preparation Preserve investigator data and traceable corrections

Independent DMC Review relevant accumulating data and recommend action Charter, appropriate independence and controlled unblinded access

Independent auditor Evaluate trial systems and compliance separately from routine operations Remain independent of the activities audited

Titles vary. Read the actual responsibility matrix, agreements and plans instead of assuming that every organisation uses the same job names. An exam question asks what the relevant person should do in the scenario, not what your employer happens to call that position.

Delegated and transferred activities

Document the activity, expected standard, responsible contact, reporting arrangements, access and essential-record retention. Clarify responsibility for subcontracted work as relevant. The sponsor or investigator needs enough information to oversee the service, including defects, significant noncompliance and important changes. Oversight is more than collecting an annual performance score.

When a provider changes, plan continuity of participant support, data integrity, product/supply handling and record access. A transition can create mismatched identifiers, duplicate accounts, missing files or unclear safety contacts. Preserve the prior records and verify the transferred information rather than treating a new vendor's contract date as proof that the handover succeeded.

Risk and issue escalation

The CRA should know whom to contact for urgent clinical concerns, product stability decisions, system defects and quality findings. Use the relevant function rather than routing every issue only to a project manager. A suspected unreported SAE may need immediate investigator/safety-team contact; a routine invoice question usually belongs in the contracts process. Document important decisions and ensure the recipient can act.

A service provider's response that an issue is outside its scope may reveal a gap in the responsibility allocation. Escalate until ownership is established; do not let the issue remain unowned because two contracts use different language. The sponsor and investigator should resolve the interface while protecting participants and maintaining reliable records.

A handoff example

A home-assessment provider records a concerning symptom but assumes the central database automatically alerts the site. The data manager assumes the provider calls the investigator. The symptom reaches a weekly listing several days later. Review the protocol instructions, consent/contact expectations, provider training, technical alert configuration and actual communication timestamps. Determine the participant impact with the responsible clinical team.

Correct the immediate gap and the interface: who recognises an urgent concern, which channel is used, who acknowledges receipt and what happens if acknowledgement fails. A new training slide alone may be inadequate if the system still gives no confirmation. Verify the revised process with appropriate evidence and retain its defined responsibilities.

Records supporting oversight

Relevant agreements, plans, qualifications, training, communications, monitoring and quality evidence should remain accessible to the responsible parties. A provider portal may be used during the study, but retention must survive its closure. Confidentiality and blinding apply to shared records. Appropriate access enables oversight; unrestricted copying can create a separate privacy or integrity problem.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ACRP CCRA Exam Content Outline .